MindWalk's Second Act: Retiring Fee-for-Service for Pharma Platform Economics

ReefIQ enterprise talks, an 80%-partnership funnel and a $30M revolver reframe a $74M microcap away from the bench and toward the data layer.

HYFT · Earnings Call · 2026-09-14

MindWalk Holdings Corp. (HYFT) is a C$74 million microcap that has spent two decades doing wet-lab biologics discovery for 19 of the top 20 global pharma companies. On its September 14 Q1 fiscal 2027 call, it talked about almost everything except the bench. Revenue came in at C$3.8 million, up 21% year over year — a fifth straight quarter of year-over-year growth — while gross margin expanded to 59% from 48%. The net loss widened to C$6.1 million from C$4.1 million of continuing-operations loss a year earlier, and cash slipped to C$7.6 million from C$11.3 million at April 30. None of that is the story. The story is a company quietly rebuilding its commercial shape around a data platform it launched in June.

The Quiet Death of Fee-for-Service

In July, CEO Jennifer Bath drew a line: “That type of fee-for-service work has actually come to an end. We are now asking people to contract us either in a partnership model or they can take a SaaS license.” — Jennifer Bath, CEO · 2026-07-22 That was qualitative. This quarter it got a number: “Today, roughly 80% of our current funnel by value is now structured this way, spanning data management, ReefIQ, and multi-target discovery.” — Jennifer Bath, Chief Executive Officer · 2026-09-14 The shift matters because it changes what MindWalk sells — not discrete projects but economics in the molecules it helps create, plus a recurring platform relationship sitting on top.

The recurring piece is ReefIQ, the substrate layer between unstructured biological data and AI models. Management is blunt that investors should not benchmark it against the old LensAI contracts: adoption of ReefIQ is "a whole new level of engagement." The company is in active negotiations with multiple large pharmaceutical companies, and the friction is not technical. “None of them are really about whether or not the platform works” — Jennifer Bath, Chief Executive Officer · 2026-09-14 — the gating factors are IT security and data governance review, multi-year procurement terms, and scoping the first deployment. Those are the objections of a system-of-record being pulled inside a client's biological data landscape, not a pilot project.

These initial ReefIQ agreements are probably going to be relatively lumpy. It's just the nature of the structure. They're going to be milestone based, there's engineering efforts at the outset, and then they become annual recurring revenue.
Richard Areglado, Chief Financial Officer · 2026-09-14

Financing the Story Without Issuing Shares

The second fresh item is the binding commitment for a USD 30 million senior unsecured revolving credit facility at a fixed 7%, drawn as needed. For a company burning roughly C$4 million a quarter on operations, with C$7.6 million of cash, this is material oxygen — and management framed it explicitly as avoiding equity: "without issuing a single share," set against a market cap that "does not reflect what we have built." It is a telling contrast with December 2025, when the financing narrative ran through an ATM and a Cayman segregated-portfolio structure for asset level financing. This quarter the revolver was bolted on without replacing that ring-fenced program structure — the Cayman parties are still roughly 90–95% through legal and tax planning.

What has quietly faded is the internal pipeline as a headline theme. "Dengue" and the internal-asset narrative that dominated fiscal 2026 calls barely surfaced; the pipeline is now mentioned generically, with new hires "to accelerate our IND enabling work." internal pipeline and discrete projects are in the transcript's vocabulary, but the commercial energy has migrated decisively to ReefIQ and platform partnerships.

Riding a Wave or Building a Private One?

Here is the contrarian read. The market's own top keywords this quarter are about tariff refunds, memory pricing, data centers and AI infrastructure — not bio-native discovery. MindWalk's story is company-unique, not a sector wave it is surfing. The closest global cousin is AI ARR, itself only a marginally related theme. The company's open-source compute milestone, validating OpenFold3 on AMD Instinct MI325X GPUs, does brush against the market's open weight model chatter — but MindWalk's framing is deliberately anti-commodity: “Models commoditize. The layer they run on compounds.” — Jennifer Bath, Chief Executive Officer · 2026-09-14 They are arguing the value accrues to the context layer, not the model — a claim the market will have to price, and one that no peer in this week's reporting cohort is confirming.

Meanwhile, the broad AI-agent wave visible across recent reporters (SailPoint's Agentic Suites, Oracle's Agentic Studio) is a wave MindWalk is only adjacent to; its LensAI reasoning layer is pitched as model-neutral rather than agentic. That keeps the equity idiosyncratic, which cuts both ways for a name with no price-tape history in this dataset.

What to Watch

Three catalysts now define this story: signing the first ReefIQ enterprise deployment, converting the 80% partnership pipeline into contracted economics, and moving a pipeline asset toward an IND. The 21% growth and the 48%-to-59% gross-margin jump suggest the recurring base is already earning its keep, but management refuses to give a timeline for the first ReefIQ signature — a disciplined choice that leaves the quarter's biggest claim unverified. For a $74 million company claiming enterprise-scale platform relevance, the next two quarters will reveal whether the partnership discussion converts or merely persists.